Skip to main content
Toggle navigation
Login
Search
Home
Back
Favorite
0
Like
Facebook
Tweet
Print
Session IV: BTKi in the Treatment of CLL
Is Minimal Residual Disease Status Useful in Stopping/Continuing Therapy in Chronic Lymphocytic Leukemia?
Wednesday, May 11, 2022
3:30 PM – 3:50 PM
Speaker(s)
Nitin Jain, MD
Associate Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas
Learning Objectives:
Incorporate guideline recommendations for cytogenetic analysis and minimal residual disease (MRD) monitoring into the care of patients with CLL/SLL